Edwards Lifesciences' PASCAL System Outperforms Medical Therapy in Tricuspid Repair Trial

By Public Technologies
  • Edwards Lifesciences’ PASCAL tricuspid repair system outperformed medical therapy alone on the CLASP II TR trial’s six-month primary endpoint.
  • Reductions in tricuspid regurgitation and improvements in patient health status persisted through one year, with low adverse event rates at 30 days.
  • Results were presented at the Transcatheter Cardiovascular Therapeutics symposium.
  • The system received FDA approval for tricuspid valve repair in October 2026, following CE Mark certification in 2020.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611021325BIZWIRE_USPR_____20261102_BW800980) on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.